AF Rhythm Focus Acesion Pharma is a Danish biotech concentrating on developing novel SK channel inhibitors to treat atrial fibrillation, signaling opportunities in partnerships or trials with cardiology device and pharma players seeking improved rhythm control therapies.

Series B Momentum Significant funding rounds totaling around €45 million in 2023, backed by Canaan, Alpha Wave, Novo Holdings and Global BioAccess Fund, indicate strong investor confidence and potential for partnering on late-stage development or co-developments.

Biotech Scale With a lean team of 11-50 employees and a capital-efficient profile, there is room for strategic collaborations in R&D outsourcing, clinical trial management, or manufacturing partnerships to scale up once programs advance.

Regulatory & Safety Emphasis The company targets safer and efficacious AF treatments with a focus on reducing proarrhythmia risk, presenting sales opportunities for safety-focused biomarkers, monitoring solutions, and risk-management tools appealing to clinicians and payers.

Global Exposure Headquartered in Copenhagen with recognized investors and a multinational funding base, Acesion may pursue international partnerships, licensing, or research collaborations to access broader markets and diverse clinical trial networks.